title: Pulmonary toxicity of recombinant interleukin-2 plus lymphokine-activated killer cell therapy.
abstract: The aim of the present investigation was to evaluate lung toxicity in 15 patients affected by metastatic melanoma of different sites, and treated with recombinant interleukin-2 (rIL-2) plus lymphokine-activated killer (LAK) cells The treatment regimen included a first and a second course of rIL-2, separated by four consecutive daily leukaphereses. Autologous LAK cells were reinfused during the second course. Lung function was monitored before and after each rIL-2 administration. In the 12 patients who could be followed until completion of the therapy, spirometric parameters and transfer factor of the lungs for carbon monoxide (TLCO) decreased significantly during the first rIL-2 course, remained stable during leukapheresis, and declined significantly further during the second rIL-2 course. In the second phase, chest radiography documented some degree of pulmonary oedema, ranging from interstitial oedema to frank pulmonary oedema. A significant dose-dependent correlation was found between the cumulative rIL-2 dose and the decline in TLCO in the first course of therapy. Moreover, patients who developed symptomatic respiratory insufficiency (World Health Organisation grade III or IV) during the second course of therapy received a higher number of LAK cells than those who did not. The data support the hypothesis that LAK cells have an additional toxic effect on the lung.
authors.affiliation: Divisione di Fisiopatologia Cardiorespiratoria, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Villani
authors.forename: M
authors.initials: M
authors.lastname: Galimberti
authors.forename: M
authors.initials: M
authors.lastname: Rizzi
authors.forename: R
authors.initials: R
authors.lastname: Manzi
mesh_terms: D000328:Adult; D002248:Carbon Monoxide / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects*; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D015979:Killer Cells, Lymphokine-Activated; D007937:Leukapheresis; D008168:Lung / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D008545:Melanoma / Q000556:secondary / Q000628:therapy*; D008875:Middle Aged; D011446:Prospective Studies; D011654:Pulmonary Edema / Q000209:etiology; D012129:Respiratory Function Tests; D013147:Spirometry
chemical_list: D007376:Interleukin-2; D002248:Carbon Monoxide